Search details
1.
High Torque teno virus load and outcome of patients undergoing allogeneic hematopoietic cell transplantation.
J Med Virol
; 96(3): e29458, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38483058
2.
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Ann Hematol
; 101(6): 1321-1331, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35352216
3.
Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.
Acta Oncol
; 61(11): 1332-1338, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36214787
4.
Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation.
Ann Pharmacother
; 56(9): 1007-1015, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35016532
5.
Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation.
J Med Virol
; 92(12): 3665-3673, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32297984
6.
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Haematologica
; 105(2): 297-316, 2020.
Article
in English
| MEDLINE | ID: mdl-31753925
7.
Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.
Br J Haematol
; 202(2): 434-436, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36999438
8.
Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.
Br J Haematol
; 188(3): e24-e27, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31742668
9.
[Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. / Toxicités hématologiques après CAR-T cells, recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).
Bull Cancer
; 2024 Apr 16.
Article
in French
| MEDLINE | ID: mdl-38631984
10.
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Blood Cancer J
; 14(1): 31, 2024 02 19.
Article
in English
| MEDLINE | ID: mdl-38374026
11.
Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Transplant Cell Ther
; 30(2): 235.e1-235.e10, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38007092
12.
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.
J Hematol Oncol
; 17(1): 2, 2024 01 07.
Article
in English
| MEDLINE | ID: mdl-38185663
13.
[Graft failure, poor graft function erythroblastopenia: Actualization of definitions, diagnosis and treatment: Guidelines from the SFGM-TC]. / Non-prise de greffe, dysfonctionnement du greffon et érythroblastopénie : mise à jour des définitions, outils diagnostiques et prise en charge : recommandation de la SFGM-TC.
Bull Cancer
; 110(2S): S67-S78, 2023 Feb.
Article
in French
| MEDLINE | ID: mdl-36307323
14.
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Bone Marrow Transplant
; 58(4): 401-406, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36624161
15.
The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Blood Adv
; 7(5): 856-865, 2023 03 14.
Article
in English
| MEDLINE | ID: mdl-36350752
16.
Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
Bone Marrow Transplant
; 58(5): 506-513, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36725978
17.
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC.
Bone Marrow Transplant
; 58(12): 1331-1338, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37653054
18.
Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.
Leuk Lymphoma
; 63(13): 3100-3104, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36528585
19.
On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.
Clin Lymphoma Myeloma Leuk
; 22(1): 34-43, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34456160
20.
Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Cancer Med
; 11(4): 1068-1080, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35048553